Oculis Holding AG (OCS) Current Assets (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Current Assets of $289.9 million for Q1 2026, up 38.07% year-over-year from $210.0 million in Q1 2025, and up 5.86% quarter-over-quarter from $273.9 million in Q4 2025.
Analysis
Oculis Holding AG (OCS) Current Assets (2021 - 2026) Analysis & Trends
Oculis Holding AG's Current Assets history runs 6 years deep, the most recent figure standing at $289.9 million for Q1 2026.
- In Q1 2026, Current Assets rose 38.07% year-over-year to $289.9 million; the TTM figure through Mar 2026 stood at $289.9 million (up 38.07% YoY), while the FY2025 annual figure was $264.0 million, up 121.42% from the prior year.
- Current Assets for Q1 2026 stood at $289.9 million, up from $273.9 million in the prior quarter.
- The five-year high for Current Assets was $289.9 million in Q1 2026, with the low at $24.6 million in Q4 2022.
- The 5-year median for Current Assets is $135.0 million (2023), against an average of $157.8 million.
- The sharpest annual moves came in 2022 and 2023: Current Assets slumped 52.81% in 2022, then jumped 363.75% in 2023.
- Oculis Holding AG's Current Assets stood at $24.6 million in 2022, then soared by 363.75% to $113.9 million in 2023, then increased by 5.15% to $119.7 million in 2024, then soared by 128.71% to $273.9 million in 2025, then rose by 5.86% to $289.9 million in 2026.
- Business Quant data shows OCS's Current Assets at $289.9 million in Q1 2026, $273.9 million in Q4 2025, and $188.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.82 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.03 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 7.22 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.76 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - | 294.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 294.88 Mn |
| Mar 31, 2026 | 289.93 Mn |
| Dec 31, 2025 | 273.87 Mn |
| Sep 30, 2025 | 188.65 Mn |
| Jun 30, 2025 | 200.75 Mn |
| Mar 31, 2025 | 209.98 Mn |
| Dec 31, 2024 | 119.74 Mn |
| Sep 30, 2024 | 128.68 Mn |
| Jun 30, 2024 | 137.82 Mn |
| Mar 31, 2024 | 97.89 Mn |
| Dec 31, 2023 | 113.88 Mn |
| Sep 30, 2023 | 130.76 Mn |
| Jun 30, 2023 | 134.98 Mn |
| Dec 31, 2022 | 24.56 Mn |
| Dec 31, 2021 | 52.04 Mn |